(June 16 17:30) Forbes.com
The stock price of Sorrento Therapeutics (NASDAQ: SRNE), a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has seen a solid 49% rise over the last twenty-one trading sessions, led by multiple positive developments...
You can find the original article
here